89282-03-1

Basic information

• Product Name: 3-iodopyridin-4-ol
• Synonyms: 3-iodopyridin-4-ol;3-Iodo-4-hydroxypyridine
• CAS NO: 89282-03-1
• Molecular Formula: C₅H₄INO
• Molecular Weight: 220.993
• Mol File: 89282-03-1.mol

Chemical Properties

• Melting Point: 303 °C(Solv: water (7732-18-5))
• Boiling Point: 263.4 °C at 760 mmHg
• Flash Point: 113.1 °C
• Appearance: /
• Density: 2.12 g/cm³
• Vapor Pressure: 0.0103mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.79±0.18(Predicted)
• CAS DataBase Reference: 3-iodopyridin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-iodopyridin-4-ol(89282-03-1)
• EPA Substance Registry System: 3-iodopyridin-4-ol(89282-03-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 89282-03-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-iodopyridin-4-ol is utilized as a building block in organic synthesis for its ability to participate in a range of organic reactions, contributing to the creation of diverse chemical compounds.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-iodopyridin-4-ol is employed as a precursor for the synthesis of biologically active molecules, highlighting its importance in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
3-iodopyridin-4-ol is used in medicinal chemistry for its potential antifungal properties, making it a candidate for the development of new antifungal agents to combat fungal infections.
Used in Drug Discovery:
3-iodopyridin-4-ol is also used in drug discovery efforts due to its potential anticancer properties, indicating its possible application in the creation of novel cancer treatments.
Used in Antifungal Applications:
3-iodopyridin-4-ol is used as an antifungal agent for its potential to inhibit fungal growth, offering a new avenue for the treatment of various fungal diseases.
Used in Anticancer Applications:
In the realm of anticancer applications, 3-iodopyridin-4-ol is used for its potential to combat cancer cells, providing a foundation for the development of new cancer therapeutics.

InChI:InChI=1/C5H4INO/c6-4-3-7-2-1-5(4)8/h1-3H,(H,7,8)

Upstream product

• 108-96-3 4-pyridone 
• 626-64-2 pyridin-4-ol 
• 497-19-8 sodium carbonate 

Downstream Products

• 89167-34-0 4-chloro-3-iodopyridine 
• 1093064-77-7 2-(5-nitro-1-trityl-1H-indazol-3-yl)-furo[3,2-c]pyridine 
• 63731-38-4 2-phenylfuro<3,2-c>pyridine 
• 89324-16-3 4-hydroxypyridine-3-carbonitrile 

Relevant articles and documents

Synthesis of Long Oxahelicenes by Polycyclization in a Flow Reactor

A series of oxahelicenes composed of ortho/meta-annulated benzene/pyridine and 2H-pyran rings were synthesized on the basis of the cobalt(I)-mediated (or rhodium(I)- or nickel(0)-mediated) double, triple, or quadruple [2+2+2] cycloisomerization of branched aromatic hexa-, nona-, or dodecaynes, thus allowing the construction of 6, 9, or 12 rings in a single operation. The use of a flow reactor was found to be beneficial for the multicyclization reactions. The stereogenic centers present in some of the oligoynes steered the helical folding in such a way that the final oxa[9]-, [13]-, [17]- and [19]helicenes were obtained in both enantiomerically and diastereomerically pure form. Specifically, the oxa[19]helicenes beat the current record in the length of a helicene backbone. Single-molecule conductivity was studied by the mechanically controllable break-junction method with a pyridooxa[9]helicene.

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

KINASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of the general formula (A) and pharmaceutical compositions thereof that inhibit protein tyrosine activity. In particular the invention relates to said compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling. Said compounds and compositions are useful for the treatment of cell proliferative diseases and conditions.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I: 1where in W is 2These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which α7 is known to be involved.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Furopyridine, thienopyridine pyrrolopyridine useful in controlling chemical synaptic transmission

Novel heterocyclic ether compounds having the formula: STR1 wherein A, m, R, X, Y1, Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.